Company updateCNBC-TV18
Biocon shares gain after US FDA approves cancer drug biosimilar
Positive+403 sources
GreyOak summary
Biocon shares rose following US FDA approval for Pebrilzo, a biosimilar to Perjeta for HER2-positive breast cancer. This marks the company's fifth oncology biosimilar approval. The drug is expected to enter the US market in the third quarter of 2028 under a licensing agreement with Genentech.
What it affects
- BioconBIOCONPositive +40
Shares gained after US FDA approval for Pebrilzo.Rolling sentiment Positive +18
Source
Read the original at CNBC-TV18More Biocon news
No other recent stories about Biocon.
All Biocon news →